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Abstract: The early and correct assessment of psychomotor agitation (PMA) is essential to ensure
prompt intervention by healthcare professionals to improve the patient’s condition, protect healthcare
staff, and facilitate future management. Proper training for recognizing and managing agitation in
all care settings is desirable to improve patient outcomes. The best approach is one that is ethical,
non-invasive, and respectful of the patient’s dignity. When deemed necessary, pharmacological
interventions must be administered rapidly and avoid producing an excessive state of sedation,
except in cases of severe and imminent danger to the patient or others. The purpose of this brief
review is to raise awareness about best practices for the management of PMA in emergency care
situations and consider the role of new pharmacological interventions in patients with agitation
associated with bipolar disorder or schizophrenia.
Keywords: agitation; bipolar disorder; loxapine; psychomotor agitation; schizophrenia
1. Introduction
Psychomotor agitation (PMA) is characterized by increased psychomotor activity, mo-
tor restlessness, and irritability. Individuals with PMA exhibit heightened responsiveness
to internal and external stimuli and experience mental tension or altered cognitive function.
PMA can occur as a manifestation of a psychiatric disorder (e.g., schizophrenia and bipolar
disorder (BD)), central nervous system disease (e.g., Parkinson’s disease, Alzheimer’s
disease or dementia), or substance abuse [1,2]. In the context of BD or schizophrenia,
patients experiencing an episode of PMA report feeling uneasy, restless, or nervous and
have little success controlling or coping with their agitation [3]. PMA symptom progression
usually follows a fluctuating course and can include aggression; however, in all cases,
escalation can result in unpredictable, dangerous, and violent behavior that requires a
rapid response on healthcare workers and clinicians [4]. Accordingly, prompt recognition
and immediate management of PMA symptoms are imperative for decreasing the risk of
harm to the patient, healthcare staff, and other individuals in the patient’s proximity [5].
It is further essential that clinicians can quickly determine the severity of agitation and
differentiate between medical and nonmedical causes to ensure appropriate treatment.
The inability to recognize and effectively address PMA behavior can result in the need for
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coercive measures such as involuntary medication, physical restraint, and seclusion [6,7],
all of which are potentially disturbing to the patient. Although international expert rec-
ommendations are available for PMA, standardized protocols and clinical support tools
for managing PMA episodes in association with a primary psychiatric condition are often
not readily available to physicians and other healthcare professionals [1,6]. Here, we
provide a brief overview of the management of PMA in emergency care settings (e.g., in
an emergency room or inpatient psychiatric context) and offer input regarding the utility
of newer pharmacological interventions for patients with agitation associated with BD
or schizophrenia.
2. Epidemiology
Data regarding the epidemiology of PMA are poorly generalizable and mainly derive
from studies conducted in specific care settings or patient populations. The reported preva-
lence of agitation in psychiatric emergency services is between 4–10% [5,8,9]. Moreover,
up to 50% of psychiatric emergency service visits involve patients affected by schizophre-
nia, BD, or dementia, who are patients in which PMA is considered a common symptom
in emergency contexts [10,11]. A study in Spain suggested that about 25% of patients
with schizophrenia and 15% of those with BD. Experience at least 1 episode of PMA
per year, with a median of 2 episodes per year [12]. In the cross-sectional multicenter
STAGE study [13], a reported 4.6% of 7295 psychiatric emergencies were agitation episodes.
Sixty-three percent of patients who experienced an episode were male and episodes most
commonly occurred in patients with schizophrenia and BD, respectively. Substance abuse
was another common diagnosis in patients with agitation episodes but rarely presented as
a single disorder and was typically associated with a psychiatric diagnosis [13]. A recent
Spanish study analyzing over 355,000 hospital discharge records reported PMA in 1.5%
of patients [14]; in this cohort, 52.8% of patients with PMA were male and 78% had two
or more comorbidities (versus 45.2–60.1% in the control group). These findings suggest
that PMA has a mild predilection towards male sex and is more common in patients with
higher disease burden, i.e., multiple comorbidities.
3. Definitions and Causes
The Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) defines agitation
as an excessive motor activity associated with a feeling of inner tension. Motor activity is
usually non-productive and repetitious and can include behaviors such as pacing, fidgeting,
hand wringing, pulling one’s clothes, and an inability to sit still. Even if aggression and
violence are not core agitation features, a progression in agitation severity can lead to
aggressive and violent behaviors [15,16]. At the first International Experts’ Meeting on
Agitation, agitation was defined as “a state where patients cannot remain still or calm, char-
acterized by internal features such as hyperresponsiveness, racing thoughts, and emotional
tension; and external ones, mainly motor and verbal hyperactivity, and communication im-
pairment” [17]. This definition, although not all-inclusive, was developed for its practical
utility in a clinical setting. Despite these attempts to define agitation, there is still a lack of
agreement regarding an exact definition for this broad and multifactorial syndrome.
One reason explaining the difficulty mentioned above in defining PMA is that many
consider it a transnosological syndrome that involves multiple and varied pathological
processes and occurs due to a diversity of psychiatric and neurological conditions [18].
Considering the nature of PMA, it may be logical to take a multi-dimensional (and multi-
disciplinary) approach to its definition that relates to its psychopathology, going beyond
the DSM-5 classification. Agitation is a multifactorial syndrome [1] associated with many
illnesses such as psychiatric disorders, intoxication/withdrawal, and other general medical
conditions [19].
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Psychiatric Disorders and Comorbid Substance Abuse
The differential diagnosis of agitation accompanying schizophrenia or BD requires
a careful evaluation of the patient and consideration of all possible factors contributing
to an agitated state. Asking the patient to report on their own state with the adminis-
tration of psychiatric interviews or self-rating scales can exacerbate agitated behaviors
and risk escalation from agitation to aggression or violence [20]. In agitation related to
schizophrenia, the patient may experience delusions (e.g., persecutory delusions) and
command hallucinations to harm others [21,22]. In BD, agitation often manifests during
manic episodes as an excess of the activity or depressive episodes as irritability and fluctu-
ating energy levels [23]. Involuntary motor activity can be a symptom of underlying or
comorbid somatic illness or a side effect of prescribed therapies for a patient’s disorder.
Akathisia related to PMA can be difficult to distinguish in patients who often report vague,
non-specific complaints such as nervousness, inner tension, discomfort, restlessness, itch-
ing, and inability to relax. Providers must differentiate between drug-induced akathisia
and agitation to avoid increasing antipsychotic or antidepressant treatment doses as an
incorrect treatment strategy [24].
PMA frequently emerges in psychiatric patients who engage in recreational substance
abuse or develop comorbid substance abuse disorder; this phenomenon is especially well-
documented in schizophrenia and BD. An estimated 50% of patients with schizophrenia
have a comorbid substance abuse disorder [23,25]. Moreover, patients with BD. who have
psychotic symptoms and engage in substance abuse have a higher risk of violent aggression,
especially during the manic phase [26]. Substances used can include methamphetamines,
opioids, nicotine, marijuana, caffeine, hallucinogenic mushrooms, and cocaine. These
substances are frequently used for self-medication (rather than pharmacological therapy).
PMA episodes are most likely to emerge due to intoxication or abstinence (e.g., opioid
withdrawal) from psychoactive substances. Identifying substance abuse as a cause or
exacerbating factor for PMA is critical for guiding subsequent treatment and specifying
strategies for long-term management.
Alcohol abuse is another frequent cause of PMA, especially in idiosyncratic reactions,
acute intoxication, or withdrawal. Subjects who exhibit PMA associated with alcohol abuse
are frequently dependent on the substance and have heavily used alcohol in the long term.
PMA can also manifest as the result of mixing alcohol with other substances, resulting in a
loss of impulse control and aggressive behaviors.
4. PMA Recognition and Assessment
PMA is an evolving phenomenon for which rapid intervention is essential to avoid
escalation to violent behavior. Tools for its evaluation must facilitate quick and easy
assessment based only on clinical observation without interviewing the patient. These
tools should provide scores and cut-offs to assess PMA severity and inform therapeutic
decision-making.
The early signs of PMA include changes in different domains [6]. In the presence of
one or more of these signs, immediate identification of PMA severity and intervention is
necessary to avoid escalation to higher levels:
• Behavioral: inappropriate verbal or motor activity, irritability, impaired self-control,
reduced cooperation, aimless wandering, complaining.
• Cognitive: temporal/spatial disorientation, decreased attention, delusion/hallucination,
refusal to communicate.
• Physical: weakness, headache, autonomic signs as tachycardia, dyspnea, sweating,
tremor, muscle tension.
The progression of agitation symptoms can be visualized as a continuum or S-shaped
curve that ranges from calm negativity to evident hostility [27]. On this curve, agitation
increases with time from mild to moderate to severe, where each category defines different
functional characteristics of the patient state. A mild level of agitation is clinically char-
acterized by fast responses, constant nervous movement, and flashes of anger. Moderate
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agitation is characterized by verbal ranting, violent responses, and non-cooperative or
paranoid behavior. Severe agitation is characterized by verbal and physical aggression,
attention deficit, lack of coherence, and predisposition to conflict. For example, signs can
evolve from complaints to repetitive phrases or movements, inappropriate or accelerated
movements, speaking loudly, prolonged eye contact, invasion of personal space, tense and
angry facial expressions, and finally result in verbal threats and openly aggressive behavior.
Moreover, agitation may be one of the main indicators of imminent and impulsive suicidal
behavior [28,29].
In real-world situations, the classification of agitation symptoms using the scheme
described above depends largely on a clinician’s experience and capacity for judgment. In
order to permit the more standardized assessment of PMA, several rating scales have been
developed to assess symptom escalation and agitation severity, including context-specific
scales. A number of scales are currently available for use in psychiatric settings (Table 1).
Generally speaking, the positive and negative symptom scale-excited component (PANSS-
EC) [30] and clinical global impression-aggression (CGI-A) [20] represent the most suitable
choices in emergency psychiatric settings. However, the effective application of these
scales in a real-world setting still depends on the observer’s skills for individuating specific
behaviors. It is essential to highlight that quantitative assessment of PMA severity cannot
be separated from a qualitative evaluation and global assessment of the patient’s situation.
Table 1. Ratings scales for psychomotor agitation in emergency care settings.
Scale No. Items Scoring Total ScoreRange Time to Complete
The Agitated Behaviors Mapping
Instrument (ABMI) 29 items 1–4 29–203
From 20 min to 1 h
observation
The Agitation Severity Scale (ASS) 21 items 0–3 0–63 10 min
The Aggressive Behavior Scale 4 items 0–3 0–12 7 days ofobservation
The Agitated Behavior Scale 14 items 1–4 14–50 30 min
The Brief Agitation Measure (BAM) 3 items 0–7(for the past week) 3–21 Few minutes
The Brief Agitation Rating Scale (BARS) 10 items 0–3 0–30 4 days observation
The Broset Violence Checklist (BVC) 6 items 0–1absent/present 0–6 Few minutes
The Clinical Global Impression Scale for
Aggression (CGI-A) 1 item 1–5 1–5 1–2 min





(for the past week) 29–203 20 min





N: No/ P: Possibly/
Y: Yes
H: in the last
1–6 months
C: current episode R:
future risk for
1–6 months
Not applicable From 30 min to afew hours
The Neurobehavioral Rating Scale-
Revised (NRS-R)
5 domains
29 items 0–3 0–87 From 20 min to 1 h
The Overt Aggression Scale (OAS) 4 domains16 items 0–4 0–16 A few minutes
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Table 1. Cont.
Scale No. Items Scoring Total ScoreRange Time to Complete
The Overt Agitation Severity Scale (OASS) 3 domains16 items 1–4 0–120 15 min observation
The Positive and Negative Syndrome
Scale-Excited Component (PANSS- EC) 5 items 1–7 5–35 Few minutes
The McNiel-Binder Violence Screening
Checklist (VSC) 5 items
0–1
absent/present 0–5 Few minutes
The Pittsburgh Agitation Scale (PAS) 4 items 0–4 0–16 A few minutes
The Ryden Aggression Scale 26 items 0–5 0–125 20 min
The State-Trait Anger Expression
Inventory (STAXI) 44 items 0–4 0–132 5–10 min
The Staff Observation Scale (SOAS) 4 events 3–10 24–30 10–15 min of eventreporting
The PANSS, initially developed in 1987 for use in patients with schizophrenia, is
composed of 30 items subdivided into three distinct groups: positive symptoms (7 items),
negative symptoms (7 items), and general psychopathology symptoms (15 items) [31].
Accordingly, the PANSS permits a broad evaluation of the patient’s psychological state,
including factors that interact with positive and negative symptomology. The PANSS-
EC (excited component) is a 5-item subscale (poor impulse control, tension, hostility,
cooperation, and excitation) in which each item is assigned a point value of 1–5. A total
score of >14 with at least >4 points on one item indicates the presence of clinically significant
PMA, and >20 corresponds with severe PMA Valid treatment response is defined as a
>40% reduction in score within 2 h of treatment. Accordingly, the PANSS-EC permits the
standardized evaluation of PMA and effective monitoring of its treatment. The PANNS-
EC has been specifically validated for the evaluation of acute psychosis and agitation in
emergency psychiatric situations [30].
The CGI is frequently used in clinical research and provides a broad evaluation of
global psychological status divided into three parts: severity (CGI-S; scored from 1—not at
all ill to 7—among the most extremely ill patients), improvement after treatment (CGI-I;
scored from 1—very much improved to 7—very much worse), and level of aggression (CGI-
A; evaluated on a scale of 1—not at all aggressive to 5—aggressive behavior). Together,
these scales provide a comprehensive evaluation of both patient status and response to
treatment. The CGI-A has been validated against the PANSS-EC [20] as a more concise
alternative under circumstances in which the PANSS-EC cannot be feasibly implemented.
In cases where a patient presenting to the emergency department is subsequently
admitted for observation and treatment, longer assessments may be useful for treatment
planning purposes and decrease the likelihood of overlooking organic disease signs. To this
extent, the brief agitation rating scale (BARS) is a useful and practical scale for the assess-
ment of agitation in a real-world context. It should be noted that the clinical relevance of
these scales is sometimes limited due to the urgency of PMA assessment and management
and PMA characteristics; in these cases, severity is often reconstructed ex post.
5. Management Strategies
The management of PMA in emergency care settings largely depends on the severity
of patient symptoms and the care context’s nature. In general, non-pharmacological
management should progress from less invasive or coercive measures to more invasive
or coercive measures [32]. In many circumstances, behavioral control methods and de-
escalation strategies such as verbal intervention, offering food or beverages, and letting
patients smoke or offering nicotine replacement are helpful to manage agitation and prevent
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its escalation into aggression or violence [33]. Therefore, the approach to an agitated
patient should start with environmental modification and verbal de-escalation in a manner
that provides physical comfort and minimizes external stimuli. Effective management is
significantly influenced by the coordination of this response among healthcare professionals
and the ability to enact environmental modification in a timely fashion [34]. To this end,
another critical goal during initial de-escalation is to ensure the safety of the patient and
those around them (e.g., remove or secure all objects that can be potentially harmful) while
respecting the patient’s dignity and ensuring that the patient does not feel threatened.
Recently, the Project BETA de-escalation workgroup proposed ten domains of verbal de-
escalation techniques to help clinicians manage agitated patients [35]. This approach aims
to reduce the use of coercive maneuvers and instead make the patient a collaborative
subject in his own care project.
Environmental issues and professional attitudes play a key role in managing an agi-
tated patient in an emergency care situation [36]. Environmental and/or organizational
measures that can reduce the risk of violence include the implementation of general safety
protocols, allocation of a reserved room, use of safety doors and metal detectors, a fast and
effective communication system to advise the staff about the admission of a patient with
a history of violent behavior, availability of security staff, easy access to a security exit,
removal of objects that may be used as weapons, minimizing external stimuli, and continu-
ous observation by staff to remove disruptive individuals when necessary. Professional
attitudes are also important for managing agitated patient. A calm, positive, empathetic,
and respectful approach by specially trained staff can limit or alleviate agitation [37,38].
In some cases, de-escalation is unsuccessful, and temporarily, physical restraint (PR)
may become necessary. The Mental Health Unit Use of Force Act issued in 2018 defines
PR as “the use of physical interaction which is proposed to avoid, restrict, or subdue the
normal movement of any part of the patient’s body.” However, PR should be used as a last
resort and only for limited periods of time as a strategy to prevent negative physical and
psychological consequences [39].
Pharmacological intervention becomes necessary when verbal and behavioral methods
fail to calm the patient. Before starting any medication, physicians should always attempt
to diagnose the most likely cause for agitation, guiding or influencing treatment choice.
This is because agitation associated with psychosis, mania, and substance abuse is mainly
correlated with alterations in catecholamines and specifically elevated dopaminergic neu-
rotransmission (and should, therefore, be amenable to treatment with anti-dopaminergic
medications), whereby decreased gamma-aminobutyric acid (GABA) transmission is the
primary characteristic of agitation associated with dementia, depression, and anxiety; it
should be treated as such [40].
The ideal treatment for the acute management of PMA in an emergency care setting
should: (1) be easy to administer and non-traumatic; (2) quickly calm the patient without
excessive sedation; and (3) if pharmacological, have a rapid onset of effect with low pharma-
cokinetic variability, as well as a low risk of adverse events and drug interactions [1,16,27].
While parenteral administration routes (intramuscular (IM), intravenous) ensure rapid
action, they are invasive and considered to be potentially traumatic to a distressed patient.
Accordingly, oral administration is the preferred route of medication for pharmacological
PMA treatment and parenteral routes are reserved for extreme cases of necessity (e.g.,
severe agitation). Unfortunately, no single therapeutic option currently available meets the
definition described above, resulting in an important unmet clinical need.
6. Pharmacological Management
Pharmacological strategies for PMA in emergency care settings should control agita-
tion or violent behavior without producing excessive sedation and should preferably avoid
invasive administration routes [41]. The pharmacological management of agitation has
traditionally employed three classes of medications: first-generation antipsychotics (FGAs),
benzodiazepines (BZDs), and second-generation antipsychotics (SGAs) [33]. Available
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pharmacological tools and emerging treatment options for PMA are outlined below and
summarized in Table 2. In the present review we focused on available parenteral and
inhaled medications.
Table 2. Parenteral and inhaled pharmacological treatments for psychomotor agitation.
Class Drug Mode ofAdmin
Dose Range























• FGAs should only be
administered during
pregnancy if the benefit
clearly outweighs the
potential risk to the fetus
• Use with caution in patients
<17 years of age.
IV 5–20
• Falls




















• Sudden death (for high
doses)































In children ≥12 years and











• The safety and efficacy of
aripiprazole injection have
not been established in
subjects ≤17 years
Ziprasidone IM 10–40 • DRESS Cardiovascular disorders
The safety and efficacy of
ziprasidone injection have not












• Administration with BDZ.
isn’t recommended due to
safety considerations.
• The safety and efficacy of
olanzapine injection have
not been established in
subjects ≤17 years
Int. J. Environ. Res. Public Health 2021, 18, 4368 8 of 14
Table 2. Cont.
Class Drug Mode ofAdmin
Dose Range
























• Use lower dosages in
children and adolescents






















• Use lower dosages in
children and adolescents

































• Useful for psychomotor
agitation in epilepsy
Italicized drugs or modes of administration are not recommended. BZD, benzodiazepine; DRESS, drug reaction with eosinophilia and
systemic symptoms; EEG, electroencephalogram; FGA, first-generation antipsychotic; IM, intramuscular; IV, intravenous; NMS, neuroleptic
malignant syndrome; SGA, second-generation antipsychotic.
6.1. First-Generation Antipsychotics
First-generation antipsychotics (FGAs) such as haloperidol and chlorpromazine have
a long history of use for the treatment of agitation in BD. and schizophrenia. The exact
mechanism of action for calming agitation is unknown but is attributed in part to a negative
effect on dopaminergic transmission in the brain, especially at the D2 receptor, which may
act to decrease motor agitation. These agents also typically exert noradrenergic, cholinergic,
and histaminergic inhibitory actions. A key benefit of haloperidol is that it is useful for the
rapid tranquilization of patients exhibiting aggression associated with psychosis, although
the use of haloperidol alone when alternatives are available may be unethical [42]. A recent
meta-analysis identified haloperidol plus promethazine or droperidol as safe and effective
options for rapid tranquilization [43]. Unfortunately, FGAs can also be associated with
unpleasant extrapyramidal side effects (e.g., tremor, slurred speech, akathisia, dystonia),
some of which appear after long-term exposure (e.g., tardive dyskinesia). Moreover, some
FGAs are structurally similar to GABA and interact with human GABA receptors at high
doses [44,45]. Among FGAs used for PMA, haloperidol is the gold standard comparator for
most trials, whereas zuclopenthixol is the treatment of choice when long-term treatment is
necessary [1].
Loxapine is an FGA approved for the treatment of acute agitation in BD. and
schizophrenia. Loxapine blocks D2, D1, and D4 dopamine receptors and also blocks
serotonin 5HT2 with the same potency [46]. In 2012, the FDA approved an inhaled for-
mulation of loxapine that uses a specific device (Staccato® One Breath Technology™).
This technology quickly vaporizes an excipient-free drug formulation to yield an aerosol
that is ideal for inhalation and produces peak plasma levels of loxapine within 2 min.
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Moreover, administration via inhalation of the Staccato® loxapine aerosol is associated
with a lower risk of adverse effects (extrapyramidal symptoms, sedative effects) than other
systemically administered antipsychotics [47,48]. The pharmacokinetic profile of inhaled
loxapine is similar to that of the intravenous formulation [49–51]. In a clinical study of
patients with schizophrenia or BD, inhaled loxapine (5 mg or 10 mg) exhibited efficacy for
mild-to-moderate agitation with a rapid onset of action as determined using PANSS-EC
scores [47]. In the PLACID study [52], inhaled loxapine attenuated agitation was measured
with the CGI scale faster than IM aripiprazole in patients with schizophrenia or BD in
both hospital and emergency settings. Moreover, patients treated with inhaled loxapine
were more often “very” or “extremely” satisfied with treatment than the aripiprazole
group. Treatments with high patient satisfaction can promote better physician-patient
relationships and stimulate patient empowerment [52].
In a majority of studies reporting safety outcomes in patients with schizophrenia or
BD, inhaled loxapine was well tolerated and did not produce excessive sedation [53–55].
The most commonly reported adverse effects were mild to moderate and included dys-
geusia, throat soreness, and sedation [50–52,56]. Severe adverse events were rare and
included excessive sedation, akathisia [51], asthenia [52], neck dystonia and oculogyric
crisis [50], and dystonia in a patient with a history of jaw clenching secondary to an-
tipsychotic treatment [47]. Inhaled loxapine is not associated with cardiovascular toxicity;
however, a primary safety issue is the potential for pulmonary adverse events. Direct
inhalation of pharmacological agents into the lungs can increase the risk of developing
or worsening asthmatic reactions, wheezing, and bronchospasm [57,58]. Although pul-
monary adverse events were uncommon and mild or moderate in reported studies, it is
noteworthy that intervention with albuterol was at times necessary to treat wheezing and
bronchospasm [50–52,56]. Gross et al. [59] demonstrated that inhaled loxapine potentially
elicits airway effects such as FEV1 reduction and bronchospasm in subjects with asthma
and chronic obstructive pulmonary disease. These effects were usually reversible with a
β-agonist bronchodilator such as salbutamol or albuterol. It is reasonable to recommend
a brief pulmonary assessment (e.g., medical history and physical examination) before
treatment with inhaled loxapine [60]. A short-acting β-agonist bronchodilator should
always be readily available in psychiatric emergency settings when choosing this drug to
treat PMA [47].
6.2. Second-Generation Antipsychotics
SGAs exert a combined inhibitory effect on both dopaminergic (D2) and serotonergic
(5-HT2A) neurotransmission. A body of research has demonstrated the efficacy of several
agents for the treatment of PMA, including aripiprazole, quetiapine, risperidone, and
ziprasidone; however, oral olanzapine is generally preferred for its favorable side effect
profile (a main concern being orthostasis), especially in comparison to other IM FGAs such
as haloperidol [44,45,61,62]. The new availability of olanzapine as an intranasal formulation
and a recent meta-analysis highlighting it as an ideal agent for rapid tranquilization make
it particularly attractive for treating episodes of PMA in emergency care settings [43,63].
Risperidone is not necessarily indicated in older patients due to a risk of hypotension [64].
IM aripiprazole is approved for the treatment of agitation associated with schizophrenia
or BD, and doses of 5–20 mg have shown the same efficacy as 2.5–10 mg haloperidol
for the treatment of PMA [61]. In a randomized control trial of droperidol, ziprasidone,
and midazolam for acute undifferentiated agitation in emergency care, ziprasidone was
less likely to require rescue medication for adequate sedation than midazolam. However,
sedative effects were somewhat delayed compared to other agents [65]. Accordingly,
expert guideline recommendations indicate the suitability of oral SGAs as first-line therapy
for acute agitation in emergency contexts [2], although an analysis of common practice
suggests that these agents are underutilized in emergency care [66].
Orally disintegrating formulations of aripiprazole, olanzapine, and risperidone have
been developed, but this administration method does not improve time to onset or offer
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other notable advantages in terms of safety or efficacy [67,68]. Sublingual asenapine is
also approved by the US Food and Drug Administration (FDA) to treat schizophrenia and
manic/mixed episodes associated with BD.
6.3. Benzodiazepines
Benzodiazepines (BDZs) are a class of sedative drugs that have been used extensively
for rapid tranquilization [69]. All benzodiazepines share a common action mechanism
and produce a similar range of effects, including anxiolytic, hypnotic, muscle relaxant,
and anticonvulsant actions. The action mechanism is related to allosteric modulation of
GABA-A receptors that increases the receptor’s affinity for its cognate ligand. For this
reason, the central nervous system depressant effects of BDZs are more prominent than
those associated with antipsychotic agents [69].
BDZ potency is determined by the affinity of drug-receptor binding. For example,
lorazepam and clonazepam have high potency, diazepam has moderate potency, and
temazepam has low potency. The time to onset depends on drug lipophilicity, with
midazolam and lorazepam being the fastest acting and oxazepam being a slower acting
BDZ [70].
Given the fast action of lorazepam, standard treatment for acute psychotic agitation
typically involves intramuscular injection of lorazepam and the FGA haloperidol. In
one study, oral lorazepam plus risperidone was as effective as this standard treatment,
suggesting that an oral BDZ combination may provide effective management of PMA
episodes [71]. The combination of haloperidol with BDZs also appears to be safe for acute
agitation in emergency contexts [72,73]. In contrast, the administration of intramuscular
olanzapine isn’t recommended with BDZs due to potential adverse effects [41].
Diazepam is also used to manage P but should be administered intravenously as it
precipitates when used IM. Moreover, its long effect duration and prolonged sedation can
be bothersome in some cases.
7. Limitations
The present work has several limitations. First, we elected to perform a brief overview
of available literature and accordingly did not perform a systematic review or meta-analysis
as perhaps this topic merits. However, authors participated in electronic database search
and selected articles for inclusion based on their own experience and judgment. Second,
the authors were all of the same nationality and work in similar clinical environments,
which may have introduced a source of bias. Finally, this article’s recommendations are
specifically in emergency care and therefore may not be applicable in all clinical settings.
8. Conclusions
The prompt recognition and management of PMA in emergency care settings and
clinical settings remain important healthcare providers’ challenges. Differential diagnosis
of the underlying cause of the PMA episode and objective grading of its severity are
necessary to inform appropriate management. Initial responses include de-escalation
and behavioral strategies to calm the patient and make them a cooperative participant in
their own care. Invasive treatment modalities (e.g., intramuscular medications) should
only be reserved for severe cases of agitation, and when pharmacological intervention is
needed, oral or other non-invasive modalities of administration are preferable. Among
traditional approaches to the pharmacological management of PMA in emergency care
settings, inhaled loxapine is emerging as a beneficial therapy associated with good efficacy,
safety, and patient satisfaction.
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